Q2 2025 Stryker Corp Earnings Call Transcript
Key Points
- Stryker Corp (SYK) reported double-digit organic sales growth of 10.2% and adjusted EPS growth of 11.4%, driven by strong demand across its product portfolio.
- The company experienced robust growth in its MedSurg and Neurotechnology segments, with 11% organic sales growth, and Orthopaedics with 9% organic growth.
- Stryker Corp (SYK) achieved its best-ever Q2 for Mako installations, both in the US and worldwide, with high utilization rates, indicating strong demand for its orthopedic robotics.
- The company raised its full-year 2025 outlook, expecting another 100 basis points of adjusted operating margin expansion, reflecting confidence in its growth and earnings power.
- Stryker Corp (SYK) continues to see strong capital demand with an elevated backlog and healthy hospital CapEx budgets, supporting future growth prospects.
- Stryker Corp (SYK) faced supply chain challenges, particularly affecting its Medical division, with disruptions expected to persist through the end of the year.
- The integration of Inari Medical experienced some disruption due to destocking and onboarding of new sales professionals, impacting short-term performance.
- The company is dealing with the impact of tariffs, with an estimated net impact of approximately $175 million in 2025, affecting cost structures.
- Stryker Corp (SYK) reported lower sales in its Emergency Care business due to continuing supply disruptions, which are expected to linger.
- The Vascular segment showed modest US organic sales growth of 1.4%, indicating potential challenges in achieving higher growth rates in this area.
Welcome to the second-quarter 2025 Stryker earnings call. My name is Megan, and I'll be your operator for today's call. At this time, all participants are in a listen-only mode. Following the conference, we will conduct a question-and-answer session. This conference call is being recorded for replay purposes.
Before we begin, I would like to remind you that the discussion during this conference call will include forward-looking statements. Factors that could cause actual results to differ materially are discussed in the company's most recent filings with the SEC. Also, the discussion will include certain non-GAAP financial measures. Reconciliation to the most directly comparable GAAP financial measures can be found in today's press release that is an exhibit to Stryker's current report on Form 8-K filed today with the SEC.
I will now turn the call over to Mr. Kevin Lobo, Chair and Chief Executive Officer. You may proceed, sir.
Welcome to Stryker's second
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
